Development of a Silica Microparticle Taggant System to Measure ART Adherence
NCT: NCT06465862 · WITHDRAWN
Brief Summary
Developing technologies to help measure and provide tools to support medication-taking behaviors (medication adherence) is an important step to ending the human immunodeficiency virus (HIV) epidemic. TruTag Technologies has pioneered the use of a microparticle system that can be incorporated into the coating of medications may help users both identify the medication they are taking and record adherence events. By using a standard smartphone camera, shining light on TruTag-coated medications automatically identifies them to an onboard smartphone app which then indirectly records the adherence event. This study evaluates the real-world usability and feasibility of operating this system among people living with HIV (PLWH).
Frequently Asked Questions
What is Development of a Silica Microparticle Taggant System to Measure ART Adherence?
Development of a Silica Microparticle Taggant System to Measure ART Adherence is a clinical trial registered under NCT06465862. Current status: WITHDRAWN.
What is the status of NCT06465862?
The current status of NCT06465862 (Development of a Silica Microparticle Taggant System to Measure ART Adherence) is: WITHDRAWN.
When did Development of a Silica Microparticle Taggant System to Measure ART Adherence start?
Development of a Silica Microparticle Taggant System to Measure ART Adherence started on 2024-09-15.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.